(Received for publication, July 31, 1996, and in revised form, October 3, 1996)
From the Howard Hughes Medical Institute and the
§ Department of Biological Chemistry, University of Michigan
Medical Center, Ann Arbor, Michigan 48109
Binding of double-stranded RNA (dsRNA) to PKR
induces autophosphorylation and activation. However, the requirement
for dsRNA in promoting dimerization and the requirement for
dimerization in PKR activation are controversial. We have studied the
dsRNA binding and dimerization requirements for the activation of PKR in vivo. Co-expression and immunoprecipitation experiments
detected an interaction between the K296P mutant and a bacteriophage
T7-epitope-tagged K64E mutant of dsRNA binding domain. In contrast, the
K64E/K296P double mutant did not form a detectable dimer with the
wild-type dsRNA binding domain. These results support that dimerization of intact PKR with the isolated dsRNA binding domain requires dsRNA
binding activity. Expression of the isolated PKR kinase domain
(residues 228-551) reduced translation of the reporter mRNA even
in the presence of PKR inhibitors. Furthermore, the isolated kinase
domain (residues 228-551) undergoes autophosphorylation and
sequentially trans-phosphorylates both mutant K296P PKR and wild-type eIF-2 in vitro. In contrast, the isolated
kinase domain (residues 264-551) lacking the third basic region was
not active. These observations lead us to propose that the dsRNA
binding domains on intact PKR inhibit kinase activity and that dsRNA
binding to intact PKR induces a conformational change to expose
dimerization sites within the dsRNA binding domain thereby promoting
dimerization and facilitating trans-phosphorylation and
activation.
Cells respond to external stimuli by rapid changes in their
translational capacity. Stress, such as growth factor depletion, heat
shock, and virus infection, rapidly inhibits protein synthesis through
phosphorylation of the subunit of the eukaryotic translation initiation factor 2 (eIF-2
) (1, 2). Several protein kinases are
known to phosphorylate eIF-2
(3). The most ubiquitous eIF-2
kinase in mammalian cells is the double-stranded
(ds)1 RNA-activated protein kinase (PKR).
PKR expression is induced by interferon as a latent form that is
activated upon binding to dsRNA (4). PKR activation and subsequent
eIF-2
phosphorylation is the primary mechanism that prevents viral
replication as part of the interferon antiviral response (5, 6).
Recently, it has become evident that PKR may also play a critical role
in regulation of cell growth (7, 8, 9), dsRNA-dependent
transcriptional regulation (10, 11, 12, 13), regulation of differentiation (14,
15), induction of cell apoptosis (16), and suppression of cell
transformation (8, 9).
PKR contains two conserved dsRNA binding motifs in its amino terminus and a serine/threonine kinase catalytic domain in its carboxyl terminus (17, 18, 19). Extensive mutagenesis studies strongly support that dsRNA binding to PKR is required for dsRNA-dependent activation (19, 20, 21, 22, 23). Mutation of the conserved lysine 64 to glutamic acid (K64E) within the first dsRNA binding motif significantly reduces dsRNA binding (19, 24). Although the structural elements for PKR required for dsRNA binding are extensively characterized, little is known about how dsRNA binding leads to PKR activation. Upon binding to dsRNA, PKR becomes autophosphorylated by a mechanism that may require dimerization. The requirement for dimerization is supported by the observations that activation of PKR displays second order kinetics (25), that PKR can be detected as a dimer by size exclusion chromatography (26), and that autophosphorylation of PKR may occur in trans (27). In vitro experiments and in vivo genetic experiments have shown the dsRNA binding domain containing the two dsRNA binding motifs is necessary and sufficient for PKR dimerization (28, 29, 30). However, at present, it is unclear whether dsRNA binding promotes dimerization of PKR.
Overexpression of catalytically inactive K296R or K296P (mutants of the
invariant lysine within the ATP binding pocket) inhibits the endogenous
PKR activity, reduces eIF-2 phosphorylation, increases protein
synthesis, and induces cellular transformation (7, 8, 9, 31, 32, 33). Our
previous studies support the hypothesis that the dominant negative
phenotype observed by mutant PKR overexpression results from
competition for binding to potential dsRNA activators and not from the
formation of inactive heterodimers (30).
To further characterize the requirement for dsRNA binding in
dimerization and activation of PKR, we studied a double mutant that was
defective in both dsRNA binding activity and kinase activity (K64E/K296P). The results show that the ability of the K296P mutant to
rescue translation requires dsRNA binding activity. Unexpectedly, co-immunoprecipitation demonstrated that the double mutant K64E/K296P PKR did not dimerize with the intact dsRNA binding domain (1-243). These results suggest that, although dsRNA binding is not required for
dimerization of the isolated dsRNA binding domain, dsRNA binding is
required for dimerization of the intact PKR molecule. In addition, we
demonstrate that the isolated kinase domain (KD) undergoes autophosphorylation and sequentially trans-phosphorylates
K296P and eIF-2 in vitro. The KD also inhibits protein
synthesis in the presence of PKR inhibitors that interfere with
dsRNA-dependent activation. These results indicate that the
isolated kinase domain (residues 228-551) is a constitutively active
kinase independent of the endogenous PKR. Based on these findings, a
model is proposed for the mechanism of dsRNA-dependent
activation of PKR.
The expression vectors used in this
study contain the same transcription unit utilizing the adenovirus
major late promoter and simian virus 40 (SV40) enhancer element. In
addition, the vectors contain the SV40 origin for replication in COS-1
cells. The dihydrofolate reductase (DHFR) expression plasmids pD61,
pMTVA, and pMT2 were described previously (34). Briefly,
pD61 contains pBR322 as a backbone, whereas pMT2 plasmids contain pUC18
as a backbone. pMT2 contains the adenovirus VAI gene, whereas
pMTVA
does not. The expression plasmid
pETFVA
was described previously (35). The K296P
expression vector pETFVA
-K296P, the PKR dsRNA binding
domain (BD, amino acid residues 1-243) expression vector
pETFVA
-BD, the K64E mutant BD expression vector
pETFVA
-K64E-BD, and the PKR kinase domain (amino acid
residues 228-551) expression vector pETFVA
-KD were
described previously (30). The K64E/K296P mutant PKR expression vector
was made by digesting pETFVA
-K296P and
pETFVA
-K64E-BD with PstI and PmeI.
The small fragment from pETFVA
-K64E-BD was isolated and
ligated to the large fragment isolated from pETFVA
-K296P
to generate pETFVA
-K64E/K296P. The expression vector
encoding the third basic region deletion mutant of PKR kinase domain
(KD
D3, residues 264-551), pETFVA
-KD
D3, was made by
polymerase chain reaction using the method previously described (30).
The sequences of the mutants were determined by the dideoxynucleotide
sequencing method (36).
COS-1 monkey kidney cells were transfected by the DEAE-dextran procedure (37). After 48 h, cells were labeled with Expre35S35S protein labeling mixture (100 µCi/ml; 1,000 Ci/mmol; DuPont NEN) for 20 min in methionine/cysteine-free minimal essential medium (Life Technologies, Inc.). Cell extracts were prepared by lysis in kinase binding buffer (24). For analysis of the dimerization of PKR, equal amounts of DNA (1 µg/ml, unless indicated in the legends) from each vector were co-transfected into COS-1 cells. Cells were labeled and harvested using the same method described above. Proteins were immunoprecipitated using anti-T7-tag monoclonal antibody (Novagen Corp., Madison, WI). Where indicated, the cell extracts were incubated at 30 °C for 30 min in the presence or absence of poly(I):poly(C) (1 µg/ml, Pharmacia Biotech Inc.). The cell extracts and immunoprecipitates were analyzed by SDS-PAGE (38). Gels were fixed in 30% methanol, 10% acetic acid, prepared for fluorography by treatment with En3Hance (DuPont NEN, Boston, MA), and dried. Dried gels were autoradiographed with BIOMAX MR film (Eastman Kodak, Rochester, NY). The co-immunoprecipitated PKR mutants and fragments were quantitated by NIH-Image (Version 1.55b, NIH, Bethesda, MD).
Total RNAs were prepared using the TriZOL method according to the
procedure provide by the manufacturer (Life Technologies, Inc.) and
analyzed by RNA Northern blot hybridization (39) following electrophoresis on formaldehyde-formamide denaturing agarose gels (40).
Probes (DHFR and -actin) were prepared by
[
-32P]dCTP labeling using Rediprimer DNA labeling
system (Amersham).
The cell extracts prepared from the transfected COS-1 cells were incubated with poly(I):poly(C) agarose beads (Pharmacia Biotech Inc.) at 30 °C for 30 min in kinase binding buffer (24). The beads were then washed extensively with the same buffer three times at room temperature. The bound proteins were analyzed by SDS-PAGE as described above.
In Vitro Kinase AssayThe K296P-T7, KD-T7, KDD3-T7,
eIF-2
, and eIF-2
51A expression vectors were transfected into
COS-1 cells as described above. At 48 h post-transfection, the
cells were lysed in kinase binding buffer (24). The expressed proteins
were immunoprecipitated using anti-T7-tag antibody and anti-eIF-2
antibody. For trans-phosphorylation assay, the proteins were
first mixed as indicated and then immunoprecipitated using the
antibodies described. The immunoprecipitates were washed twice with
kinase binding buffer (24) and once with kinase assay buffer (20 mM HEPES, pH 7.5, 50 mM KCl, 1.5 mM
dithiothreitol, 2 mM Mg(OAc)2, 2 mM
MnCl2, and 0.1 mM ATP) and assayed for in vitro kinase activity. The in vitro kinase assay was
performed in 25 µl of kinase assay buffer with 5 µCi of
[
-32P]ATP at 30 °C for 30 min. The samples were
analyzed by SDS-PAGE (38) followed by autoradiography with BIOMAX MR
film (Eastman Kodak).
The steady-state levels of the overexpressed PKR mutants
and eIF-2 were measured in cell extracts obtained as described
above. Equal volumes of cell extracts were resolved by SDS-PAGE and
electroblotted to nitrocellulose membranes. The membranes were
immunoblotted with anti-T7-tag antibody and anti-eIF-2
monoclonal
antibody (kindly provided by Dr. Henshaw) and analyzed by the alkaline phosphatase immunoblotting detection system as described by the supplier.
The transient transfection system used in this study has been
described (30, 34, 35, 41, 42). By using this system, we have
previously shown that K296P mutant PKR, the intact dsRNA binding domain
(BD, residues 1-243), and the first dsRNA binding motif (D1, residues
1-123) can inhibit endogenous PKR activity and stimulate DHFR
translation in this system. To further evaluate the dsRNA binding
requirement for mutant PKR to mediate this dominant negative effect, an
expression plasmid for synthesis of the PKR double mutant K64E/K296P
was constructed. This mutant produces a catalytically inactive PKR that
is defective in dsRNA binding capability (19, 24, and see below). The
ability for this double mutant to inhibit endogenous PKR activity was
compared with K296P, BD, and mutant K64E-BD by co-transfection of COS-1
cells with pD61. DHFR protein synthesis was quantitated by
[35S]methionine/cysteine labeling of cells and analyses
of harvested cell extracts by SDS-PAGE. In parallel, cells were
harvested for quantitation of mRNA by Northern blot hybridization
analysis. Transfection of pD61 with the pETFVA vector
alone into COS-1 cells detected a low level of DHFR synthesis (Fig.
1A, lane 2) that was above the
background observed in cells that did not receive pD61 DNA (Fig.
1A, lane 1). Co-transfection of pD61 with either
K296P or BD increased DHFR synthesis compared to co-transfection with
the pETFVA
vector alone (Fig. 1A, lanes
2, 3, 5), whereas co-transfection of either
K64E/K296P or K64E-BD did not alter DHFR synthesis (Fig. 1A,
lanes 4 and 6). Northern blot analysis
demonstrated the DHFR mRNA level did not change upon
co-transfection with the PKR mutants and fragments (Fig. 1B,
lanes 2-6), demonstrating that the changes in DHFR
synthesis were due to changes in mRNA translational efficiency.
Rescue of DHFR translation by PKR requires
dsRNA binding activity. COS-1 cells were co-transfected with the
DHFR expression vector pD61 in the presence of the pETFVA
expression vector alone (lane 2) or of pETFVA
containing the indicated PKR inserts. Lane 1 received only
pETFVA
DNA. Equal amounts (4 µg/10-cm plate) of the two
plasmid DNAs were used. The transfected cells were labeled with
[35S]methionine/cysteine and analyzed as described under
"Experimental Procedures." A, analysis of total cell
extracts. The migration of DHFR, intact PKR, and the dsRNA binding
domain BD are indicated. B, total RNA from cells transfected
in parallel was isolated, and the mRNA levels for DHFR and
-actin were analyzed by Northern blot hybridization. C,
the expressed PKR mutants were affinity-purified with poly(rI):poly(rC)
agarose beads and analyzed by SDS-PAGE.
The dsRNA binding potential for the different PKR mutants and fragments was measured and correlated to translational stimulation. [35S]methionine/cysteine-labeled cell extracts were prepared from the transfected COS-1 cells and were incubated with poly(I):poly(C) agarose beads. After extensive washing, the bound proteins were analyzed by SDS-PAGE. Proteins of 69 kDa and 33 kDa, representing intact PKR and BD of PKR, were observed (Fig. 1C, lanes 3-6). The intensities of the bands corresponding to the K64E mutants were reduced compared to the wild-type K296P and BD, indicating a defect in dsRNA binding (Fig. 1C, lanes 4 and 6 versus 3 and 5). These results support the hypothesis that dsRNA binding activity is required for the dominant negative phenotype as measured by this in vivo translational stimulation assay.
We then asked whether dsRNA binding is required for dimerization of
intact PKR. We have previously described an immunoprecipitation assay
to detect PKR dimerization that relied on one of the interacting partners being expressed with a bacteriophage T7-epitope tag at the
carboxyl terminus (30). K296P PKR or the double mutant K64E/K296P PKR
was co-transfected with K64E/BD-T7 or BD-T7. Analysis of the total cell
extracts indicated that K296P, K64E/K296P, BD-T7, and K64E/BD-T7 were
expressed in COS-1 cells at a high level (Fig. 2,
lanes 1-4). Immunoprecipitation of the cell extracts with
limiting amounts of anti-T7 antibody specifically adsorbed each
T7-tagged fragment (Fig. 2, lanes 5, 6,
9, and 10) that were not detected in the absence
of the T7-epitope tag on the BD (Fig. 2, lanes 7,
8, 11, and 12). Immunoprecipitation of
T7-tagged K64E/BD detected the expected polypeptide at 33 kDa as well
as some co-immunoprecipitation of a 69-kDa polypeptide that represented
K296P PKR (Fig. 2, lanes 5 and 9). In addition,
the amount of co-immunoprecipitation of K296P PKR with K64E/BD-T7 was
increased by incubating the cell extracts with poly(I):poly(C) prior to
immunoprecipitation (Fig. 2, lanes 5 and 9).
Under similar conditions, dimerization was not detected with the
K64E/K296P double mutant PKR and the wild-type BD-T7, even in the
presence of poly(I):poly(C) (Fig. 2, lanes 6 and
10). These results show that, in contrast to the isolated BD
where dimerization is independent of dsRNA, the dimerization between
K296P and BD was dsRNA-dependent. We do not think the increased co-immunoprecipitation detected by poly (I):poly(C) addition was due to cross-linking through dsRNA binding since poly(I):poly(C) did not increase the amount of BD-T7 that was immunoprecipitated in the presence of limiting amounts of anti-T7 antibody. We believe the low level of dimerization detected in the
absence of poly(I):poly(C) was due to a low level of cellular dsRNA
present that induced dimerization.
Previous results demonstrated that the isolated kinase domain (KD) can
phosphorylate eIF-2 and inhibit translation in vivo (30,
33). However, it is not known if the KD directly phosphorylates eIF-2
or whether eIF-2
phosphorylation occurred indirectly
through phosphorylation and activation of the COS-1 cell endogenous
wild-type PKR. To discriminate between these possibilities, COS-1 cells were co-transfected with a KD expression vector
(pETFVA
-KD or the KD catalytically defective mutant
pETFVA
-K296P-KD) in the presence of a DHFR expression
vector that either lacks (pMTVA
) or contains (pMT2) the
adenovirus VAI RNA gene. DHFR was highly expressed in cells transfected
with either pMTVA
or pMT2 (Fig. 3,
lanes 2 and 3 versus 1). Co-transfection of the
wild-type KD with the DHFR reporter plasmid significantly reduced DHFR
synthesis (Fig. 3, lanes 2 and 3 versus 4 and
6) even in the presence of VAI RNA provided by pMT2 (Fig. 3,
lane 2 versus 4), whereas co-transfection of the K296P-KD
with the reporter gene did not alter DHFR synthesis (Fig. 3,
lanes 2 and 3 versus 5 and 7).
Co-transfection experiments with an expression vector encoding the
vaccinia virus E3L gene product, a double-stranded RNA-binding protein
that inhibits PKR activity in vivo
(pETFVA
-E3L, Ref. 23), did not rescue DHFR translation in
the presence of KD, even though E3L was expressed at a high level
sufficient to inhibit endogenous PKR activity (Fig. 3, lane
9, arrow; Ref. 35). These results support the
hypothesis that the isolated kinase catalytic domain of PKR is
constitutively active and can directly phosphorylate eIF-2
,
independent of COS-1 cell endogenous wild-type PKR.
To further characterize the kinase activity of the isolated kinase
domain of PKR, an in vitro kinase assay was performed. Two
forms of KD (KD and KDD3) were analyzed that differed in the
presence of the D3 domain (residues 226-263 present in KD and absent
in KD
D3). The T7-epitope-tagged K296P, KD, KD
D3, eIF-2
, and
eIF-2
51A were individually expressed in COS-1 cells. The
steady-state level of the expressed proteins, analyzed by Western
analysis, demonstrated that all proteins were expressed at significant
levels (Fig. 4B). The expressed PKR mutants
were immunoprecipitated using anti-T7-tag antibody and incubated with [
-32P]ATP in in vitro kinase assay buffer
for activity assay. Under these conditions, KD was autophosphorylated
(Fig. 4A, lane 2), whereas K296P and KD
D3 was
not phosphorylated (Fig. 4A, lanes 1 and
3). The ability of KD to trans-phosphorylate PKR
and eIF-2
was then examined using the same in vitro
kinase assay. The KD was mixed with K296P, KD
D3, eIF-2
, or
eIF-2
51A and then incubated with [
-32P]ATP in the
kinase assay buffer. KD was autophosphorylated in all the samples (Fig.
4A, lanes 4-7). In addition, the K296P mutant of
PKR and wild-type eIF-2
were also phosphorylated in trans (Fig. 4A, lanes 4 and 6). In the same
experiment, KD
D3 and eIF-2
51A (a Ser
Ala mutation at the site
of phosphorylation) were not phosphorylated (Fig. 4A,
lanes 5 and 7). The results demonstrate that the
isolated kinase domain of PKR (KD) is an active kinase that can
phosphorylate substrates similar to wild-type PKR. The results also
suggest that the D3 basic region of PKR may contain the in
vitro KD-catalyzed phosphorylation site(s).
The requirements for dsRNA binding to and sequentially activating
PKR have been studied intensively through mutagenesis of the PKR dsRNA
binding domain as well as dsRNA molecules, such as adenovirus VAI RNA
(19, 20, 21, 22, 23, 24). The two dsRNA binding motifs in PKR appear to cooperate to
promote high affinity stable binding to dsRNA. An intriguing aspect
about the dsRNA activation of PKR is that it displays a bell-shaped activation curve, where high concentrations of dsRNA inhibit PKR activation. Based on these observations, two models for the
dsRNA-dependent activation of PKR were proposed. One model
proposes that PKR functions as a monomer, and activation involves
intramolecular autophosphorylation that is dependent upon proper
occupancy of the two dsRNA binding sites (43). Another model proposes
that each PKR molecule binds to one dsRNA molecule, and activation
results from bridging of two PKR molecules to elicit intermolecular
autophosphorylation (25). This latter model is supported by the
kinetics of activation being second order with respect to enzyme
concentration (25) and the fact that autophosphorylation can occur in
trans (27). In addition to the above models, a third model
proposes that PKR exists as a dimer. The presence of dsRNA or other
activators of PKR (such as heparin) can stabilize the dimer and promote
a conformational change to an active state (44). The support for an
RNA-mediated dimerization requirement for PKR activation came from
in vitro studies showing that deletion of the two dsRNA
binding motifs (amino acids 98-243 deleted) yielded an inactive kinase
(45). We have previously characterized a kinase domain fragment
containing 15 extra amino acids at the amino terminus of the kinase
domain. This enzyme did not detectably dimerize (30); however, it was active in vivo as measured by its ability to increase
eIF-2 phosphorylation (30) and to inhibit translation (Fig. 3),
consistent with another report (46). In addition, this kinase domain
was also active in an in vitro kinase assay. It undergoes
autophosphorylation and sequentially trans-phosphorylates
the K296P mutant of PKR as well as eIF-2
(Fig. 4). A Ser
Ala
mutant at residue 51 in eIF-2
was not phosphorylated (Fig. 4),
supporting that phosphorylation of eIF-2
occurred at the natural
site. The additional residues apparently required for kinase activity
of the isolated kinase domain belong to a third basic amino acid-rich
region (amino acids 233-271) (45). This region is also required for
the KD to act as a substrate for the isolated KD. At present it is not
known if this region contains a necessary contact point required for intermolecular autophosphorylation or whether it contains the primary
phosphorylation sites. Recently, this region was identified to contain
phosphorylated threonine residues.2 The
translational inhibition mediated by the kinase domain was not rescued
by the PKR inhibitors adenovirus VAI RNA or the vaccinia virus E3L gene
product. Both of these PKR inhibitors are known to inhibit PKR
activation in a dsRNA-dependent manner through different
mechanisms (5, 35). Vaccinia virus E3L is a dsRNA-binding protein that
likely binds and sequesters dsRNA PKR activators in the cell (35). In
contrast, adenovirus VAI RNA binds to the dsRNA binding site within PKR
and prevents its activation by dsRNA (5). Since both of these
inhibitors do not inhibit the translational suppression mediated by KD,
it suggests that the isolated kinase domain directly phosphorylates
eIF-2
, and this does not occur indirectly through phosphorylation of
endogenous PKR. We know the endogenous PKR activity is inhibited under
conditions of VAI RNA or E3L expression in COS-1 cells (5, 35). Thus,
our results suggest that the isolated kinase domain of PKR is a
dsRNA-independent and constitutively active eIF-2
kinase. None of
the above proposed models for dsRNA-dependent activation
can easily explain the observation that the isolated kinase domain of
PKR is constitutively active and can phosphorylate eIF-2
in the
absence of dsRNA binding and/or dimerization. Thus, there is a need for
alternative hypotheses. We propose a model for the
dsRNA-dependent activation of PKR to help direct further
experimentation to elucidate the possible molecular interactions
between the dsRNA binding domains and the kinase domain.
In this study, an in vivo COS-1 cell transfection system was used to study how dsRNA binding and/or dimerization leads to activation of PKR. Transfection of expression vectors encoding either the K296P mutant or the dsRNA binding domain of PKR rescued protein synthesis inhibition of a reporter mRNA that was mediated by endogenous PKR activation (Fig. 1A). However, the ability to rescue protein synthesis was destroyed by mutation of the K64E within the dsRNA binding domain (Fig. 1A). Analysis of poly(I):poly(C) binding affinity showed that the K64E mutation significantly reduced the poly(I):poly(C) binding (Fig. 1C). Thus, the ability to rescue protein synthesis by either the K296P mutant intact PKR or the isolated dsRNA binding domain required dsRNA binding activity, as previously shown (30). The ability of these mutants to dimerize was measured by their ability to co-immunoprecipitate with a T7-bacteriophage-tagged fragment of the dsRNA binding domain (amino acids 1-243). The results demonstrated that mutation of K64E within intact PKR destroyed its ability to dimerize with the isolated dsRNA binding domain (Fig. 2), indicating that dsRNA binding activity was required for dimerization. Whereas addition of poly(I):poly(C) increased dimerization of intact K296P PKR with the K64E-mutated dsRNA binding domain (K64E/BD), poly(I):poly(C) addition had no effect on the inability for the K64E/K296P double mutant to dimerize with the wild-type dsRNA binding domain (Fig. 2). These results are consistent with observations showing a dsRNA-dependent interaction between the dsRNA binding domain and intact PKR (29). However, these findings conflict with mutagenesis studies of the isolated dsRNA binding domain where either K60A (28) or K64E (30), both mutations that destroy dsRNA binding activity, did not prevent dimerization of the mutant dsRNA binding domain with either intact K296P PKR or the isolated dsRNA binding domain. The discrepancy in the results can be explained if dsRNA binding is only required for intact PKR dimerization, but is not required for dimerization of the isolated dsRNA binding domain. We propose that dimerization of the isolated PKR dsRNA binding domain is dsRNA-independent since its dimerization sites are exposed as a consequence of deletion of the kinase domain. This interpretation underscores the caution that needs to be taken in drawing conclusions from mutagenesis experiments using isolated domains of a protein, a situation where the isolated domain may behave differently than when in context of the intact protein.
The above observations lead us to propose a model for the
dsRNA-dependent activation of PKR that is consistent with
previous observations (28, 29, 30) (Fig. 5). We propose that
the dsRNA binding domains on intact PKR serve as an inhibitor of the kinase, possibly by preventing dimerization or by serving as a pseudosubstrate. Upon dsRNA binding to intact PKR, a conformational change occurs that exposes the site(s) for dimerization. At the same
time, the conformational change liberates the kinase domain from the
inhibitory dsRNA binding domain and promotes autophosphorylation in
trans. In contrast to intact PKR, the isolated dsRNA binding domain BD can dimerize independent of dsRNA, and the isolated kinase
domain can phosphorylate eIF-2 without dimerization.